• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

    3/15/21 4:45:13 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email
    SC 13D/A 1 ecl_mrkr13da03152021.htm SCHEDULE 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 13)*

    MARKER THERAPEUTICS, Inc.

    (Name of Issuer)

    COMMON STOCK, $0.0010 PAR VALUE PER SHARE

    (Title of Class of Securities)

    57055L107

    (CUSIP Number)

    William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    March 15, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

     
    CUSIP No. 57055L107   13D/A   Page 2 of 7
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    EASTERN CAPITAL LIMITED
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    WC
       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

    ¨

       
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       
             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.   SOLE VOTING POWER
     
    -0-
      8.   SHARED VOTING POWER
     
    3,966,668
      9.   SOLE DISPOSITIVE POWER
     
    -0-
      10.   SHARED DISPOSITIVE POWER
     
    3,966,668
             
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,966,668
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.0%
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
                             

     

    * As of the filing date and as described in Items 4, 5(a) and 5(b), Eastern Capital Limited beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

     
     

     

     
    CUSIP No. 57055L107   13D/A   Page 3 of 7
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    PORTFOLIO SERVICES LTD.
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    OO
       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

    ¨

       
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       
             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.   SOLE VOTING POWER
     
    -0-
      8.   SHARED VOTING POWER
     
    3,966,668
      9.   SOLE DISPOSITIVE POWER
     
    -0-
      10.   SHARED DISPOSITIVE POWER
     
     3,966,668
             
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,966,668
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.0%
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
                             

     

    * As of the filing date and as described in Items 4, 5(a) and 5(b), Portfolio Services Ltd. beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

     
     

     

     
    CUSIP No. 57055L107   13D/A   Page 4 of 7
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    KENNETH B. DART
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    OO
       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

    ¨

       
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       
             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.   SOLE VOTING POWER
     
    -0-
      8.   SHARED VOTING POWER
     
    3,966,668
      9.   SOLE DISPOSITIVE POWER
     
    -0-
      10.   SHARED DISPOSITIVE POWER
     
     3,966,668
             
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,966,668
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.0%
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
                             

     

    *As of the filing date and as described in Items 4, 5(a) and 5(b), Kenneth B. Dart beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

     
     

     

     
             
    CUSIP No. 57055L107   13D/A   Page 5 of 7

     

    Explanatory Note: This Amendment No. 13 to Schedule 13D (this “Amendment No. 13”) relates to shares of common stock, par value $0.0010 per share (the “Common Stock”), of MARKER THERAPEUTICS, Inc., (the “Issuer”). This Amendment No. 13 amends the original Schedule 13D filed with the U.S. Securities and Exchange Commission (“SEC”) by the Reporting Persons as previously amended by Amendments No. 1 through 12 (the “Schedule 13D”). Except as otherwise specified in this Amendment No. 13, all previous Items are unchanged. Defined terms used herein but not otherwise defined have the meanings set forth in the Schedule 13D.

    Item 4. Purpose of Transaction.

    The Reporting Persons sold an aggregate 500,000 shares of the Issuer’s Common Stock in open market transactions.

    Date Number of Shares Sold Weighted Average Selling Price
    March 15, 2021 500,000 1.85771

     

    (1)The Price reported is a weighted average price. These shares of Common Stock were sold through a broker dealer in multiple transactions at prices ranging from $ 1.85 to $1.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

    The Reporting Persons intend generally to dispose of additional shares of Common Stock, subject to various factors, including but not limited to market conditions and other factors that the Reporting Persons may deem relevant to their investment decisions. However, the Reporting Persons have no specific plans or proposals to dispose of any specific number of shares of Common Stock or at any specific prices and the Reporting Persons reserve the right to change their current intentions. Except as otherwise described above, the Reporting Persons have no plans or proposals that relate to or would result in any transaction, event or action enumerated in paragraph (a) through (j) of Item 4 of Schedule 13D.

    Item 5.  Interest in Securities of the Issuer.

    Item 5(a) – (c)

    As of the date hereof, Eastern Capital Limited beneficially owns 3,966,668 shares of the Issuer’s Common Stock, representing 5.0% of the Issuer’s outstanding Common Stock. Eastern Capital Limited has shared voting and dispositive power of the shares it beneficially owns with its parent, Portfolio Services Ltd., and Kenneth B. Dart.

    Portfolio Services Ltd., as the owner of all the outstanding shares of Eastern Capital Limited, indirectly beneficially owns 3,966,668 shares of the Issuer’s Common stock, representing 5.0% of the Issuer’s outstanding Common Stock. Portfolio Services Ltd. has shared voting and dispositive power of the shares it beneficially owns.

    As a result of Kenneth B. Dart’s ownership of all of the outstanding shares of Portfolio Services Ltd., he indirectly beneficially owns 3,966,668 shares of the Issuer’s Common Stock, representing 5.0% of the Issuer’s outstanding Common Stock. Kenneth B. Dart has shared voting and dispositive power of the shares he beneficially owns.

    The percentage ownership is based on 79,303,072 shares of the Issuer’s Common Stock outstanding, as at March 15, 2021.

    There have been no reportable transactions with respect to the Issuer’s Common Stock within the last 60 days by the Reporting Person other than as described in this Statement on Schedule 13D.

     

     
     

     

     

     
             
    CUSIP No. 57055L107   13D/A   Page 6 of 7

     

    Item 5 (d) Not Applicable

    Item 5 (e)

    On March 15, 2021, the Reporting Persons ceased to be the beneficial owner of more than five percent of the shares of Issuer’s Common Stock.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended and supplemented as follows:

    The information set forth in Item 4 of this Amendment No. 13 is incorporated by reference into this Item 6.

     

    Item 7. Material to Be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement

     

     
     

     

     
    CUSIP No. 57055L107   13D/A   Page 7 of 7

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Eastern Capital Limited

    03/15/2021

    Date

     

    /s/ Kenneth B. Dart

    Signature

     

    Kenneth B. Dart, Director

    Name/Title

     
    Portfolio Services Ltd.

    03/15/2021

    Date

     

    /s/ Kenneth B. Dart

    Signature

     

    Kenneth B. Dart, Director

    Name/Title

     
    Kenneth B. Dart

    03/15/2021

    Date

     

    /s/ Kenneth B. Dart

    Signature

     

    Kenneth B. Dart

    Name/Title

             
     

     

    Get the next $MRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/26/24 4:01:17 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/23/24 4:40:48 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/17/24 6:25:14 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/26/21 10:38:04 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/15/21 4:45:13 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

      HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc

      4/1/25 8:00:14 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

      Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 Strategic financing to support cli

      3/31/25 8:45:00 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Marker International with a new price target

      Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

      3/5/25 7:37:58 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics downgraded by Roth Capital with a new price target

      Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      2/17/22 6:14:24 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Marker Therapeutics with a new price target

      Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

      3/25/21 6:18:22 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Financials

    Live finance-specific insights

    See more
    • Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

      Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

      2/16/22 4:30:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

      HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

      2/8/22 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

      HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

      11/10/21 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

      CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

      8/28/24 8:00:00 AM ET
      $KRRO
      $MRKR
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St

      3/25/24 5:45:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Elms Steve

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:20:34 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Knobil Katharine

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:19:38 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Eansor Norman David

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:18:35 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    SEC Filings

    See more
    • Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/20/25 8:32:01 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Marker Therapeutics Inc.

      10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/15/25 5:00:50 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marker Therapeutics Inc.

      SCHEDULE 13G/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/15/25 4:13:40 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care